Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEED: Ipragliflozin in older type 2 diabetes patients with HFpEF
jRCTs051180139Completed
- Sponsor
- Kotobuki Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ipragliflozin in type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Kotobuki Pharmaceutical Co., Ltd. Primary endpoints: Change in E/e' and Change in e'. Started Oct 2017; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCTs051180139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180139.